Bradley, Quintiles, SkyePharma deal

BDY completed its previously announced acquisition of QTRN's dermatology subsidiary, Bioglan Pharmaceuticals Co. (Malvern, Penn.), for $183 million in cash (see BioCentury, June 14). The closing trigg...